Re: An invitation to join the conversation here on Agoracom
in response to
by
posted on
Jun 22, 2018 11:12AM
I agree with KayakerBC. We won't hear anything about xB3-001 human results for a while. On the slide that Kayaker posted, which can also be found in the Corporate Presentation, the company projects the first patient, first visit (FPFV) for xB3-001 Phase 1 as November 2019. That is ~16 months out. Then add on the time for additional enrollment, treatment, and trial analysis and we are 18+ months out.
BearDownAZ